You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
威高推腹腔鏡手術輔助機械人 擬挑戰直覺外科(ISRG.US)「達文西」壟斷地位
阿思達克 06-14 12:20
內媒報道, 威高集團醫療器械事業部總經理王炳強表示,6月起腹腔鏡手術輔助機械人「妙手-S」可面向普通外科銷售。 數據顯示,截至2020年底,中國導入的腹腔鏡手術輔助機械人數量為189部,而直覺外科(Intuitive Surgical)(ISRG.US)的「達文西」市佔率為100%。在推進醫療產業國產化的中國政府的支持等因素下,美國企業的壟斷情況有望被打破。 據悉,威高的產品是佩戴3D眼鏡進行操作,相較於盯著被外罩覆蓋的顯示器進行操作的「達文西」,更能減輕醫生的疲勞。威高認為,即使是使用5G的遠程手術,自家產品也具有優勢。 此外,威高的價格競爭力也是優勢。根據海通國際證券的數據顯示,「達文西」在中國的售價高達350萬美元。而威高的售價僅為1,400萬元人民幣(約197萬美元),相當於半價。由於「達文西」價格昂貴,手術機械人在中國的普及率低於歐美,中國市場佔全球的份額只有5%。 浦銀國際證券1月發布的報告顯示,除「達文西」外,中國衛生部門還向內地4家企業頒發醫療器械生產許可證。浦發銀行預計,2032年中國機械人輔助腹腔鏡手術系統市場規模將擴大至400億元人民幣,十年將增長近十倍。中國公司將能夠利用有關增長來降低價格和提高質量。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account